Eye diseases are associated with visual impairment, reduced quality of life, and may even lead to vision loss. The efficacy of available treatment of eye diseases is not satisfactory. The unique environment of the eye related to anatomical and physiological barriers and constraints limits the bioavailability of existing agents. In turn, complex ethiopathogenesis of ocular disorders that used drugs generally are non-disease specific and do not act causally. Therefore, there is a need for the development of a new therapeutic and preventive approach. It seems that matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have a significant role in the development and progression of eye diseases and could be used in the therapy of these disorders as pharmacological targets. MMPs and TIMPs play an important role in the angiogenesis, epithelial-mesenchymal transition, cell invasion, and migration, which occur in ocular diseases. In this review, we aim to describe the participation of MMPs and TIMPs in the eye diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye syndrome, glaucoma, and ocular cancers, posterior capsule opacification focusing on potential mechanisms.

The objective of this study was to investigate the phytochemical composition, antioxidant and cytotoxic potential of aronia leaf crude phenolic-extract (ACE) and purified phenolic-rich extract (APE) on human intestinal cells (CCD 841 CoN) and colon cancer cells (SW-480 and HT-29). UPLC-Q-TOF-MS analysis confirmed that aronia leaves are rich in structurally diverse polyphenols (25 and 42 compounds for ACE and APE, respectively). Chlorogenic acid and quercetin-3-rutinoside were most abundant in both aronia extracts. The sum of detected polyphenols varied significantly between extracts ranging from 32.8 mg/g (ACE) to 436.3 mg/g (APE). The biological potential of aronia extracts was confirmed by applying in vitro antioxidant and cytotoxic assays. The results of antioxidant activity (ABTS and FRAP) indicate that APE showed 2-fold stronger antioxidant properties compared to ACE. APE revealed a stronger cytotoxic effect on SW-480 and HT-29 cells than ACE (MTT test). After 48 -hours of incubation, APE was found to inhibit SW480 cell growth by 50% vs. control at 194.35 mu g/mL, while for HT-29 cells it was observed at 552.02 mu g/mL. In the case of ACE, IC50 has not been reached for SW-480 cells after 48 -hours of treatment, but for HT-29 it was 794.84 mu g/mL. Moreover, the viability was significantly decreased in a concentration- and time-dependent manner for both cancer cell lines. Examined extracts showed selective inhibitory potential against colon cancer cells. However, after 72 h incubation with CCD 841 CoN cells, the obtained IC50 values for APE and ACE were 594 mu g/mL and 709 mu g/mL respectively. This suggests that aronia leaves are valuable natural-based products that may support the treatment as chemopreventive agents in colorectal cancer.

Background/Objectives: Numerous studies have demonstrated the health benefits of polyphenols found in aronia fruits; however, little is known about how aronia leaf polyphenols impact colorectal cancer (CRC). This study aimed to evaluate the in vitro anti-metastatic and anti-invasive activity of crude aronia leaf extract (ACE) and purified phenolic-rich aronia leaf extract (APE) against two CRC cell lines (SW-480 and HT-29). Methods: Migration and invasion potential of ACE and APE were evaluated. Moreover, ELISA and gelatin zymography were performed to detect translational and activity changes in CRC cells after aronia extracts treatment. Results: We found that a 100 µg/mL concentration of ACE and APE almost entirely downregulated the migration and invasion of SW-480 cells, showing greater effectiveness than HT-29 cells. The observed inhibition was concentration-dependent and statistically significant. Additionally, extracts reduced the product of MMP-2 and MMP-9 gene expression at the protein level and simultaneously inhibited the activity of both MMPs. An APE at 300 µg/mL for SW-480 and 600 µg/mL for HT-29 resulted in a notable reduction in MMP-2 protein synthesis by 72% and 50%, respectively. In contrast, MMP-9 protein synthesis decreased by 48% and 59% in HT-29 cells treated with 300 µg/mL and 600 µg/mL of ACE, respectively. The levels of gelatinase activity were similar for both CRC lines, and the APE tested at a concentration of 300 µg/mL reached almost the IC₅₀ value after 48 h of incubation. Conclusions: Based on the presented results, we provided an experimental foundation for future in vitro and in vivo studies on the potential effects and activities of aronia leaves.

Introduction: Free fatty acid receptors (FFARs) are G protein-coupled receptors that divide into 4 subtypes; FFAR2 and FFAR3 are activated by short-chain fatty acids, while FFAR1 and FFAR4 - by long-chain fatty acids. Recent studies show the potential involvement of FFARs in the pathophysiology of colorectal cancer (CRC). A decrease in FFAR2 and FFAR4 gene expression is observed in patients with CRC. The aim of our study was to evaluate the anti-cancer effect of FFAR2 and FFAR4 stimulation by selective synthetic agonists in in vitro and in vivo models of CRC. Materials and methods: FFAR2 agonist, 4-CMTB, and FFAR4 agonist, GSK137647 were used. Cell viability (CCD 841 CoN and SW-480) was determined after 48 h incubation with tested compounds using MTT assay. Real-time qPCR and Western Blot were used to identify changes in FFARs expression. Migration and invasion were characterized by commercially available tests. Colitis-associated CRC (CACRC) mouse model was induced by azoxymethane and dextran sodium sulfate. Results: 4-CMTB and GSK137647 significantly reduced cancer cell growth as well as migration and invasion capacities. Both synthetic compounds increased FFAR2 and FFAR4 expression in SW-480 cells. Neither 4-CMTB nor GSK137647 influenced the course of AOM/DSS-induced CACRC in mice, however, 4-CMTB elevated FFAR2 protein expression in mouse tissues. Conclusion: We presented that stimulation of FFAR2 and FFAR4 may inhibit CRC cell viability and migration and that the FFAR2 and FFAR4 expression decreased in CRC can be restored by treatment with respective agonists, indicating new promising pharmacological targets in CRC treatment.

Colorectal cancer (CRC) is among the three most commonly diagnosed malignancies worldwide and remains a major public health challenge, emphasizing the need for effective preventive strategies. Considering the current chemotherapy limitations of key agents, natural products widely researched as dietary supplements can complement conventional treatments. This review concentrates on Aronia melanocarpa (black chokeberry), including its fruits, leaves and pomace, as a rich source of bioactive compounds with well-documented anticancer properties. Notably, A. melanocarpa contains high levels of polyphenols such as cyanidin-3-galactoside, cyanidin-3-arabinoside, chlorogenic acid, quercetin, and epicatechin, as well as biologically active polysaccharides, including pectins and arabinogalactans. These compounds, through their antioxidant and anti-inflammatory activities, are involved in modulating apoptosis pathways specifically targeting cancer cells. Moreover, their complexes may enhance chemopreventive efficacy through synergistic mechanisms. Recent studies show that supplementation with aronia products can improve inflammatory markers such as interleukin-6 and tumor necrosis factor alpha, highlighting its potential role in modulating the tumor microenvironment. Collectively, these findings position A. melanocarpa as a promising candidate for use in integrative strategies aimed at the prevention and adjunctive treatment of CRC.

The treatment of inflammatory bowel diseases (IBDs), particularly ulcerative colitis and Crohn’s disease, remains a challenge. As the available therapeutic options have limited efficacy and various side effect, there is a need to identify new inflammatory modulators that can influence IBD. Natural polyphenols and polyphenol-rich extracts have been found to have preventive and therapeutic potential, including various anti-inflammatory effects. In this study, the inhibition of the formation of mediators associated with intestinal inflammation, remodelling, and angiogenesis by the spent hop extract (SHE), a polyphenol-rich extract from Humulus lupulus L., and its flaxseed polysaccharide-based encapsulates was examined using tumour necrosis factor alpha (TNF-α)-stimulated human small intestinal epithelial (HIEC-6) and large intestinal epithelial (CCD841CoN) cells. Also, we assessed the activity of the tested agents after in the vitro-simulated gastrointestinal digestion process. SHE strongly inhibited the expression of pro-inflammatory cytokines, mainly IL-1β and TNF-α, as well as the expression and activity of type IV collagenases (MMP-2 and MMP-9); these effects resulted from the suppression of NF-κB, ERK and Akt signalling pathways. We also proved the protective effect of encapsulation process against the reduction in the bioaccessibility of SHE, observed under the influence of digestion process. Our results provide initial evidence on the potential utility of SHE and its encapsulates in IBD.